Docetaxel Clinical Trials

• Randomized Phase II Study of Preoperative Docetaxel or CDDP+Docetaxel for c-Stage IB-II NSCLC(JCOG0204-MF)
  ClinicalTrials.gov Identifier: NCT00132639 - Active, not recruiting
  Pulmonary Neoplasm
  
• AG-013736 in Combination with Docetaxel versus Docetaxel Alone for Patients with Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00076024 - Active, not recruiting
  Breast Cancer
  
• Study Comparing Concomitant Docetaxel + Gemcitabine to Sequential Therapy of Docetaxel Followed by Gemcitabine
  ClinicalTrials.gov Identifier: NCT00294385 - Active, not recruiting
  Breast Cancer
  
• OCSTUD Docetaxel+Cisplatin+Cyclophosphamide Versus Docetaxel+Carboplatin in Ovarian Cancer
  ClinicalTrials.gov Identifier: NCT00452985 - Active, not recruiting
  Ovarian Neoplasms
  
• A Study of Docetaxel Monotherapy or DOXIL®/CAELYX® and Docetaxel in Patients with Advanced Breast Cancer
  ClinicalTrials.gov Identifier: NCT00091442 - Active, not recruiting
  Cancer of Breast
  
• Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00429871 - Active, not recruiting
  Breast Cancer
  
• Docetaxel and Carboplatin Versus Docetaxel as Second Line Treatment in Patients With NSCLC.
  ClinicalTrials.gov Identifier: NCT00430651 - Recruiting
  Non-Small Cell Lung Cancer
  
• Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00521274 - Recruiting
  Prostatic Neoplasms
  
• Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients
  ClinicalTrials.gov Identifier: NCT00271323 - Active, not recruiting
  Non-Small-Cell Lung Carcinoma
  
• Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients
  ClinicalTrials.gov Identifier: NCT00193323 - Active, not recruiting
  Lung Cancer
  
• Docetaxel in Combination with GVAX ® Vaccine for Prostate Cancer Vs Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate Cancer With Pain
  ClinicalTrials.gov Identifier: NCT00133224 - Recruiting
  Prostate Cancer
  
• Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
  ClinicalTrials.gov Identifier: NCT00049296 - Active, not recruiting
  Cancer
  
• Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer
  ClinicalTrials.gov Identifier: NCT00393939 - Recruiting
  Breast Neoplasms
  
• Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients with Non-Small-Cell Lung Carcinoma (NSCLC)
  ClinicalTrials.gov Identifier: NCT00082472 - Active, not recruiting
  NSCLC
  
• Docetaxel in Combination with Iressa in Previously Treated Patients with Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00137761 - Active, not recruiting
  Metastatic pancreatic carcinoma
  
• Preoperative Treatment of Breast Cancer with Two Different Sequential Treatment Regimens
  ClinicalTrials.gov Identifier: NCT00149214 - Active, not recruiting
  Breast Neoplasms
  
• Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00151047 - Active, not recruiting
  Prostate Cancer
  
• Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00040807 - Active, not recruiting
  Head and Neck Cancer
  
• Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00226239 - Active, not recruiting
  Cancer
  
• Ketoconazole Plus Docetaxel to Treat Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00032825 - Recruiting
  Prostatic Neoplasms
  
• Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer
  ClinicalTrials.gov Identifier: NCT00415285 - Recruiting
  Breast Neoplasms
  
• Evaluation of Tumor Factors in Breast Cancer Treated With Docetaxel and Capecitabine
  ClinicalTrials.gov Identifier: NCT00156312 - Active, not recruiting
  Breast Cancer
  
• Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer
  ClinicalTrials.gov Identifier: NCT00191243 - Active, not recruiting
  Breast Cancer
  
• Docetaxel Plus Cisplatin Followed by Gemcitabine vs. Gemcitabine Plus Cisplatin Followed by Docetaxel for NSCLC
  ClinicalTrials.gov Identifier: NCT00173888 - Recruiting
  Non-Small Cell Lung Cancer
  
• Influence of Garlic on Docetaxel Metabolism in Patients with Breast Cancer
  ClinicalTrials.gov Identifier: NCT00076193 - Recruiting
  Breast Neoplasms
  
• Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00049088 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00148070 - Active, not recruiting
  Metastatic breast cancer
  
• Docetaxel and Gemcitabine Compared With Docetaxel and Cisplatin in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00004884 - Active, not recruiting
  recurrent pancreatic cancer; stage IVA pancreatic cancer; stage III pancreatic cancer; stage IVB pancreatic cancer; adenocarcinoma of the pancreas
  
• Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00055770 - Active, not recruiting
  Head and Neck Cancer
  
• Safety of ABR-217620 in Combination with Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer.
  ClinicalTrials.gov Identifier: NCT00132379 - Active, not recruiting
  Carcinoma, Non-Small-Cell Lung
  
• Hormone Suppression and Radiation Therapy for 6 Months with/without Docetaxel for High Risk Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00116142 - Recruiting
  Prostate Cancer
  
• Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00087035 - Active, not recruiting
  adenocarcinoma of the prostate; recurrent prostate cancer
  
• Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00084786 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Docetaxel in Treating Older Women With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00025493 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Docetaxel and GEM 231 in Treating Patients with Recurrent or Refractory Solid Tumors
  ClinicalTrials.gov Identifier: NCT00004864 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00084734 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• MS 209 Plus Docetaxel in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00004886 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00146042 - Active, not recruiting
  HER-2 Positive Metastatic Breast Cancer
  
• A Study of Docetaxel Plus Carboplatin in Patients with Hormone Refractory Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00134706 - Active, not recruiting
  Prostate Cancer; Cancer of the Prostate; Cancer of Prostate
  
• Docetaxel in Treating Patients With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00008411 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00004923 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• ZD6474 and Docetaxel in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00054093 - Active, not recruiting
  Non-small cell lung cancer
  
• Phase 1-2a Dose-Ranging Study of TLK286 in Combination with Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00047801 - Active, not recruiting
  Carcinoma, Non-Small-Cell Lung
  
• Docetaxel and Lapatinib With or Without Combination Chemotherapy or Docetaxel and Trastuzumab With Combination Chemotherapy in Treating Women With Locally Advanced, Inflammatory, or Resectable Breast Cancer
  ClinicalTrials.gov Identifier: NCT00450892 - Recruiting
  Breast Cancer
  
• Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel Or Doxorubicin in Locally Advanced Breast Cancer
  ClinicalTrials.gov Identifier: NCT00123929 - Recruiting
  Breast Cancer
  
• Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00089609 - Recruiting
  Prostatic Neoplasms
  
• Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer
  ClinicalTrials.gov Identifier: NCT00041093 - Active, not recruiting
  recurrent cervical cancer; cervical squamous cell carcinoma
  
• Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel
  ClinicalTrials.gov Identifier: NCT00527449 - Recruiting
  Primary Breast Cancer
  
• Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate
  ClinicalTrials.gov Identifier: NCT00085228 - Active, not recruiting
  adenocarcinoma of the prostate; recurrent prostate cancer; stage IV prostate cancer
  
• Docetaxel and Carboplatin in Treating Women With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00005963 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Docetaxel Combined With Estramustine in Treating Patients With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00003066 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Mitoxantrone With or Without Docetaxel in Treating Women With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00002544 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Docetaxel in Treating Older Women With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00104624 - Active, not recruiting
  Quality of Life; stage IV breast cancer; recurrent breast cancer
  
• Estramustine, Docetaxel, and Thalidomide to Treat Advanced Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00078650 - Recruiting
  Prostatic Neoplasms
  
• Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer
  ClinicalTrials.gov Identifier: NCT00028483 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Gemcitabine, Docetaxel, and Capecitabine in Treating Patients with Cancer of Unknown Primary Origin
  ClinicalTrials.gov Identifier: NCT00119314 - Active, not recruiting
  newly diagnosed carcinoma of unknown primary; recurrent carcinoma of unknown primary
  
• Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer
  ClinicalTrials.gov Identifier: NCT00004081 - Active, not recruiting
  recurrent ovarian epithelial cancer; peritoneal cavity cancer
  
• Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
  ClinicalTrials.gov Identifier: NCT00052845 - Active, not recruiting
  adenocarcinoma of the prostate; recurrent prostate cancer; stage IV prostate cancer
  
• Vinorelbine and Docetaxel in Treating Women With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00006682 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
  ClinicalTrials.gov Identifier: NCT00571675 - Recruiting
  Hormone Refractory Prostate Cancer
  
• Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer
  ClinicalTrials.gov Identifier: NCT00039520 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Docetaxel with Either Cetuximab Or Bortezomib As First-Line Therapy in Treating Patients with Stage III Or Stage IV Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00118183 - Active, not recruiting
  Non-small cell lung cancer
  
• Erlotinib and Docetaxel with Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
  ClinicalTrials.gov Identifier: NCT00113347 - Recruiting
  Head and Neck Cancer
  
• Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00006104 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Phase I Trial of Docetaxel With Perifosine
  ClinicalTrials.gov Identifier: NCT00399087 - Active, not recruiting
  Neoplasms
  
• Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients with Unresectable Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00040885 - Active, not recruiting
  Anorexia; Cachexia; Fatigue; Non-small cell lung cancer
  
• Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy
  ClinicalTrials.gov Identifier: NCT00046826 - Active, not recruiting
  adenocarcinoma of the prostate; stage IV prostate cancer; recurrent prostate cancer
  
• Gemcitabine and Docetaxel to Treat Bone and Soft Tissue Cancers
  ClinicalTrials.gov Identifier: NCT00070772 - Recruiting
  Osteosarcoma; Sarcoma, Ewing's; Chondrosarcoma
  
• Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00079118 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer; Male Breast Cancer
  
• Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00002866 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer; Neutropenia
  
• Docetaxel and Epirubicin as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma of the Stomach
  ClinicalTrials.gov Identifier: NCT00075465 - Active, not recruiting
  adenocarcinoma of the stomach; stage III gastric cancer; stage IV gastric cancer
  
• Docetaxel and Cisplatin in Treating Patients With Untreated Stage IIIA Non-small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00005868 - Active, not recruiting
  stage IIIA non-small cell lung cancer
  
• Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer
  ClinicalTrials.gov Identifier: NCT00005800 - Active, not recruiting
  stage IIIB breast cancer; stage IIIA breast cancer; inflammatory breast cancer
  
• A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers.
  ClinicalTrials.gov Identifier: NCT00177255 - Active, not recruiting
  Cancer
  
• Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00193570 - Active, not recruiting
  Cancer
  
• Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00280098 - Active, not recruiting
  Prostatic Neoplasms
  
• Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00088998 - Active, not recruiting
  Male Breast Cancer; recurrent breast cancer; stage IV breast cancer
  
• Adjuvant Chemoradiotherapy Using Cisplatin and Docetaxel After Complete Resection in Treating Patients With Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
  ClinicalTrials.gov Identifier: NCT00084435 - Active, not recruiting
  Hypopharyngeal Cancer; Laryngeal Cancer; lip and oral cavity cancer; Oropharyngeal Cancer; paranasal sinus and nasal cavity cancer; ...
  
• Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
  ClinicalTrials.gov Identifier: NCT00004066 - Active, not recruiting
  adult soft tissue sarcoma; ovarian sarcoma; small intestine cancer; uterine sarcoma
  
• Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.
  ClinicalTrials.gov Identifier: NCT00159471 - Recruiting
  Pancreatic Cancer
  
• Phase I Study of ZD4054 and Docetaxel in Patients With Metastatic HRPC
  ClinicalTrials.gov Identifier: NCT00314782 - Active, not recruiting
  Prostate Cancer
  
• Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer
  ClinicalTrials.gov Identifier: NCT00041067 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Rapid Hormone Cycling With Testosterone and Leuprolide Combined With Docetaxel in Treating Patients With Recurrent or Metastatic Adenocarcinoma (Cancer) of the Prostate
  ClinicalTrials.gov Identifier: NCT00070369 - Active, not recruiting
  adenocarcinoma of the prostate; recurrent prostate cancer; stage IV prostate cancer
  
• Docetaxel in Treating Children With Recurrent Solid Tumors
  ClinicalTrials.gov Identifier: NCT00002825 - Active, not recruiting
  recurrent childhood brain stem glioma; recurrent childhood rhabdomyosarcoma; recurrent neuroblastoma; recurrent childhood ependymoma; ...
  
• SGN-15 And Docetaxel in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00031603 - Active, not recruiting
  recurrent non-small cell lung cancer; stage IV non-small cell lung cancer
  
• Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III Breast Cancer
  ClinicalTrials.gov Identifier: NCT00004175 - Active, not recruiting
  stage IIIB breast cancer; stage IIIA breast cancer
  
• Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck
  ClinicalTrials.gov Identifier: NCT00084318 - Active, not recruiting
  Hypopharyngeal Cancer; Laryngeal Cancer; lip and oral cavity cancer; Oropharyngeal Cancer
  
• Docetaxel in Treating Patients Who Have Undergone Surgery for Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00054509 - Active, not recruiting
  stage I prostate cancer; stage II prostate cancer; stage III prostate cancer; adenocarcinoma of the prostate
  
• Docetaxel in Treating Patients With Solid Tumors
  ClinicalTrials.gov Identifier: NCT00003565 - Active, not recruiting
  adult solid tumor; Breast Cancer; Head and Neck Cancer; kidney and urinary cancer; thorax and respiratory cancer
  
• Phase I Study of Satraplatin (JM-216) in Combination with Docetaxel
  ClinicalTrials.gov Identifier: NCT00125411 - Recruiting
  Advanced Solid Tumors
  
• Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC
  ClinicalTrials.gov Identifier: NCT00319800 - Active, not recruiting
  Non-Small Cell Lung Cancer
  
• Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone
  ClinicalTrials.gov Identifier: NCT00493766 - Active, not recruiting
  Hormone Refractory Prostate Cancer
  
• Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00049283 - Active, not recruiting
  Hypopharyngeal Cancer; Laryngeal Cancer; lip and oral cavity cancer; Nasopharyngeal Cancer; Oropharyngeal Cancer
  
• Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00042939 - Active, not recruiting
  adenocarcinoma of the pancreas; stage IVA pancreatic cancer; stage IVB pancreatic cancer
  
• Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00030407 - Active, not recruiting
  stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer
  
• Docetaxel or Paclitaxel in Treating Women With Unresectable Locally Advanced or Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00006120 - Active, not recruiting
  stage IV breast cancer; stage IIIA breast cancer; recurrent breast cancer; stage IIIB breast cancer
  
• Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer
  ClinicalTrials.gov Identifier: NCT00054275 - Active, not recruiting
  recurrent breast cancer; stage IV breast cancer; Male Breast Cancer
  
• Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
  ClinicalTrials.gov Identifier: NCT00003560 - Active, not recruiting
  Endometrial Cancer; Fallopian Tube Cancer; ovarian epithelial cancer; peritoneal cavity cancer
  
• Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00066677 - Active, not recruiting
  adenocarcinoma of the pancreas; recurrent pancreatic cancer; stage IVA pancreatic cancer; stage IVB pancreatic cancer
  
• Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases
  ClinicalTrials.gov Identifier: NCT00080678 - Active, not recruiting
  adenocarcinoma of the prostate; recurrent prostate cancer; stage IV prostate cancer; bone metastases